Ascentage pharma announces its novel bcl-2 inhibitor lisaftoclax approved by china nmpa, ushering in a new era for the treatment of cll/sll

Rockville, md. and suzhou, china, july 10, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel bcl-2 selective inhibitor lisaftoclax (apg-2575) has been approved by china's national medical products administration (nmpa) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) who have previously received at least one systemic therapy including bruton's tyrosine kinase (btk) inhibitors, which makes lisaftoclax the first bcl-2 inhibitor receiving conditional approval and marketing authorization for the treatment of patients with cll/sll in china, and the second bcl-2 inhibitor approved globally.
AAPG Ratings Summary
AAPG Quant Ranking